What Croda International Doubters Got Wrong

If you only glanced at Croda International’s headlines, the story might look muddled. Regulatory worries, capacity risks and debate over fair value made the stock easy to question at the start. For Croda International shareholders, the return over the past year was 28.3%, including dividends. If you had been weighing those clashing October 2025 narratives back then, what in the original evidence could have justified taking that risk?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

If the move has made Croda International harder to judge, start where the gap is still open and scan 6 high quality undervalued stocks.

The Two Croda International Stories Investors Had To Weigh

The shares cost £27.61 at the start of the period, and Croda International sat between two very different stories that both felt plausible.

On the optimistic side, the bullish narrative put fair value at £35.23, assuming revenue growth of 5.1% a year and profit margins reaching 13.2% as bio-based chemicals and expansion in Asia and Latin America supported higher returns.

The bearish view argued for fair value of £23, warning that tighter regulation and potential bans on key ingredients could restrict the product set and limit revenue growth.

What The Croda International Results Actually Tested

The clearest data point came from Croda International’s H1 2026 report. Total revenue was £880.5m versus £855.8m a year earlier, while net income moved from £61.2m to £78.7m and net margin rose from 7.2% to 8.9%. That pattern lent more weight to the optimistic case that focused on profitability, although it did not yet reach the margin levels in either narrative.

The hinge assumption here was margin improvement. When you test a story like this in another business, track whether net income and margin move in the same direction as the original thesis, not just whether revenue shifts.

What Croda International's Price Already Assumes

Croda International shares trade at £33.9, and this Narrative’s Fair Value sits below that market quote. The current gain of 28.3% over the past year leaves the cautious Narrative focused less on headlines and more on how product mix, regional swings and cost programs translate into steadier earnings.

Anyone paying today’s price is effectively assuming Croda International can sustain mid single digit organic growth with structurally higher margins. The question is how that expectation holds up against the risk that a narrow set of beauty actives, patchy pharma projects or weaker crop markets keep profit trends bumpier than hoped.

"The main thing that has to go right is that Croda International converts its innovation led growth, regional expansion and transformation savings into sustained higher quality earnings without being derailed by lumpier pharma projects or weaker crop markets. The current numbers and valuation together imply a share price that already reflects Croda International delivering mid single digit organic growth with structurally higher margins over time."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Where Could You Get There Earlier?

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 35% below our estimate - targets underpenetrated energy-transition mandates where institutions appoint first external managers.
• Company 2 - 27% below our estimate - rolls out adviser and direct platforms designed to keep retirement savings relationships longer.
• Company 3 - 24% below our estimate - ramps automated in-house supplement production after securing distributors for everyday-consumption channels.

That is three of the list. See all 9 companies with the balance sheet to back it up →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com